Eli Lilly and Company, Thermo Fisher Scientific, Gilead Sciences, AbbVie, Abbott Laboratories, Merck & Co., Inc., and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market prescription drugs, over-the-counter medicines and related healthcare products. Their prices often react sharply to clinical trial results, regulatory approval decisions, patent expirations and shifts in healthcare policy or insurance coverage. Investors in pharmaceutical stocks seek both growth from successful drug launches and income from established companies’ dividends. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded up $17.08 on Friday, reaching $701.51. The company had a trading volume of 8,211,278 shares, compared to its average volume of 6,346,453. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53. The firm's 50 day simple moving average is $764.55 and its 200-day simple moving average is $794.63. The firm has a market capitalization of $663.95 billion, a PE ratio of 45.85, a PEG ratio of 0.98 and a beta of 0.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.
Read Our Latest Research Report on LLY
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded up $4.92 on Friday, reaching $489.96. The company had a trading volume of 2,462,453 shares, compared to its average volume of 3,069,315. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88. The firm's 50 day simple moving average is $434.83 and its 200-day simple moving average is $460.05. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $185.01 billion, a PE ratio of 28.34, a PEG ratio of 2.61 and a beta of 0.74.
Read Our Latest Research Report on TMO
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
GILD stock traded down $0.65 on Friday, hitting $118.37. 8,859,738 shares of the company's stock were exchanged, compared to its average volume of 6,401,320. Gilead Sciences has a 12-month low of $72.89 and a 12-month high of $121.83. The firm has a 50 day moving average price of $111.88 and a two-hundred day moving average price of $108.42. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market cap of $146.87 billion, a P/E ratio of 23.58, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33.
Read Our Latest Research Report on GILD
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV stock traded up $1.97 on Friday, hitting $206.65. 4,430,806 shares of the company's stock were exchanged, compared to its average volume of 4,938,490. AbbVie has a 12-month low of $163.81 and a 12-month high of $218.66. The firm has a 50 day moving average price of $191.08 and a two-hundred day moving average price of $192.20. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a market cap of $365.06 billion, a P/E ratio of 98.41, a price-to-earnings-growth ratio of 1.33 and a beta of 0.50.
Read Our Latest Research Report on ABBV
Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
ABT stock traded up $2.38 on Friday, hitting $131.66. 6,784,441 shares of the company's stock were exchanged, compared to its average volume of 6,973,725. Abbott Laboratories has a 12-month low of $110.33 and a 12-month high of $141.23. The firm has a 50 day moving average price of $131.40 and a two-hundred day moving average price of $131.20. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The stock has a market cap of $229.15 billion, a P/E ratio of 16.50, a price-to-earnings-growth ratio of 2.50 and a beta of 0.70.
Read Our Latest Research Report on ABT
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
MRK stock traded up $1.59 on Friday, hitting $84.35. 10,479,282 shares of the company's stock were exchanged, compared to its average volume of 12,027,316. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $120.30. The firm has a 50 day moving average price of $81.18 and a two-hundred day moving average price of $83.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a market cap of $210.69 billion, a P/E ratio of 13.00, a price-to-earnings-growth ratio of 0.89 and a beta of 0.38.
Read Our Latest Research Report on MRK
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Novo Nordisk A/S stock traded up $1.48 during trading hours on Friday, hitting $52.43. 15,912,328 shares of the stock traded hands, compared to its average volume of 26,343,580. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The firm's 50 day moving average price is $64.96 and its 200-day moving average price is $70.34. The stock has a market capitalization of $234.10 billion, a price-to-earnings ratio of 14.40, a P/E/G ratio of 1.80 and a beta of 0.63. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74.
Read Our Latest Research Report on NVO
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
MarketBeat All Access